Calcium metabolism

Product name

PTH 1-84 Intact, Human

Range7 - 210 pg /ml
Sensitivity1.57 pg/ml
Incubation time3.5 hours
Sample volume25 ┬Ál
Sample type

Serum, EDTA plasma

Sample preparation

Serum samples are stable up to 8 hours at 2 – 8°C or 4 months at -20 °C or below.

Reference values

10.4 – 66.5 pg/ml



Cross reaction

Human PTH 1–34: 2%; human PTH 39–84: 0.02%


Synthetic human intact PTH 1-84


Antibodies directed against human PTH 39-84 and PTH 1-34, detect intact PTH.

Tests96 Tests
Intended use

PTH (Parathyroid hormone, Parathormone, Parathyrin) is biosynthesized in the parathyroid gland as a preproparathyroid hormone, a larger molecular precursor consisting of 115 amino acids. Following sequential intracellular cleavage of a 25-amino acid sequence, pre-proparathyroid hormone is converted to an intermediate, a 90-amino acid polypeptide, proparathyroid hormone. By additional proteolytic modification, proparathyroid hormone is then converted to parathyroid hormone, an 84 amino acid polypeptide. In healthy individuals, regulation of parathyroid hormone secretion normally occurs via a negative feedback action of serum calcium on the parathyroid glands. Intact PTH is biologically active and clears very rapidly from the circulation with a half-life of less than four minutes. PTH undergoes proteolysis in the parathyroid glands, but mostly peripherally, particularly in the liver but also in the kidneys and bone, to give N-terminal fragments and longer lived C-terminal and Mid-region fragments. Intact PTH assays are important for the differentiation of primary hyperparathyroidism from other (nonparathyroid-mediated) forms of hypercalcemia, such as cancer, sarcoidosis and thyrotoxicosis. The measurement of parathyroid hormone is the most specific way of making the diagnosis of primary hyperparathyroidism. In the presence of hypercalcemia, an elevated level of parathyroid hormone virtually establishes the diagnosis. In over 90 % of patients with primary hyperparathyroidism, the parathyroid hormone will be elevated. The most common other cause of hypercalcemia, namely hypercalcemia of malignancy, is associated with suppressed levels of parathyroid hormone or PTH levels within the normal range. When intact PTH level is plotted against serum calcium, the intact PTH concentration for patients with hypercalcemia of malignancy is almost always found to be inappropriately low when interpreted in view of the elevated serum calcium. Unlike C-terminal and Mid-region PTH, which typically are grossly elevated in subjects with renal insufficiency, intact PTH assays are less influenced by the declining renal function. PTH values are typically undetectable in hypocalcemia due to total hypoparathyroidism, but are found within the normal range in hypocalcemia due to partial loss or inhibition of parathyroid function. Recent studies supported the existence of a large „non PTH 1-84 fragment“ missing a part of the aminoterminal site of the molecule. All „Intact PTH“ assays cross-react with this fragment. It has been shown that this fragment may cause wrongly increased detections levels in dialysis patients. For this reason it is recommended to use the „Bioactive Intact PTH“ assay for dialysis patients.

Product informations

Back to overview